Skip to main content

3 Result(s)

within Emi Kishino Remove this filter

and

  1. Article

    Open Access

    Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

    Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-...

    Ryohei Ogata, Emi Kishino, Wataru Saitoh, Yoshikazu Koike… in Breast Cancer (2021)

    Download PDF (1021 KB) View Article

  2. No Access

    Article

    Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells

    A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib, has been used to treat patients with estrogen receptor (ER)-positive (+) and human epidermal growth factor receptor (HER) 2-negative (−) advanced bre...

    Emi Kishino, Ryohei Ogata, Wataru Saitoh, Yoshikazu Koike, Yusuke Ohta… in Breast Cancer (2020)

  3. No Access

    Article

    Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers

    The hedgehog (Hh) signaling pathway plays important roles in cell proliferation, malignant progression, invasion and metastasis, and the expansion of cancer stem cells (CSCs). Comprehensive immunohistochemical...

    Junichi Kurebayashi, Naoki Kanomata, Yoshikazu Koike, Yusuke Ohta… in Breast Cancer (2018)